Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Cytokine targeting in rheumatoid arthritis.

Bui VL, Brahn E.

Clin Immunol. 2019 Sep;206:3-8. doi: 10.1016/j.clim.2018.04.001. Epub 2018 Apr 3. No abstract available.

PMID:
29621613
2.

IgG4-related disease of the mitral valve demonstrated by immunohistochemistry.

Tiong BK, Fishbein GA, Brahn E.

Ann Rheum Dis. 2018 Sep;77(9):1384-1385. doi: 10.1136/annrheumdis-2018-213042. Epub 2018 Feb 1. No abstract available.

PMID:
29437558
3.

Microscopic polyangiitis with dermatomyositis.

Bauer EM, Brahn E.

Eur J Rheumatol. 2017 Dec;4(4):291-293. doi: 10.5152/eurjrheum.2017.17008. Epub 2017 Aug 29.

4.

Tofacitinib Response in Juvenile Idiopathic Arthritis (JIA) and Collagenous Colitis.

Tseng B, Amighi A, Bradford K, Wang HL, Getzug TE, Brahn E.

J Clin Rheumatol. 2016 Dec;22(8):446-448. No abstract available.

PMID:
27870773
5.

Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions.

Lakhanpal A, Brahn E.

Clin Rheumatol. 2016 Dec;35(12):2869-2875. Epub 2016 Oct 6. Review.

PMID:
27714482
6.

Suppression of collagen-induced arthritis with a serine proteinase inhibitor (serpin) derived from myxoma virus.

Brahn E, Lee S, Lucas A, McFadden G, Macaulay C.

Clin Immunol. 2014 Aug;153(2):254-63. doi: 10.1016/j.clim.2014.05.003. Epub 2014 May 17.

PMID:
24845791
7.

Advances in rheumatoid arthritis animal models.

Moudgil KD, Kim P, Brahn E.

Curr Rheumatol Rep. 2011 Oct;13(5):456-63. doi: 10.1007/s11926-011-0200-z.

8.

A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis.

Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE.

J Rheumatol. 2011 May;38(5):846-54. doi: 10.3899/jrheum.100602. Epub 2011 Feb 1.

PMID:
21285160
9.

Rheumatoid arthritis therapy: advances from bench to bedside.

Choi SI, Brahn E.

Autoimmunity. 2010 Nov;43(7):478-92. doi: 10.3109/08916931003674717. Review.

PMID:
20429843
10.

Mucocutaneous leishmaniasis masquerading as Wegener granulomatosis.

Brahn E, Pegues DA, Yao Q, Craft N.

J Clin Rheumatol. 2010 Apr;16(3):125-8. doi: 10.1097/RHU.0b013e3181d52c96.

PMID:
20375822
11.

Systemic sclerosis: bilateral improvement of Raynaud's phenomenon with unilateral digital sympathectomy.

Wasserman A, Brahn E.

Semin Arthritis Rheum. 2010 Oct;40(2):137-46. doi: 10.1016/j.semarthrit.2009.08.002. Epub 2009 Oct 30. Review.

PMID:
19878974
12.

Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice.

Lourenço EV, Procaccini C, Ferrera F, Iikuni N, Singh RP, Filaci G, Matarese G, Shi FD, Brahn E, Hahn BH, La Cava A.

J Immunol. 2009 Jun 15;182(12):7415-21. doi: 10.4049/jimmunol.0804214.

13.

Angiogenesis inhibitors for the treatment of chronic autoimmune inflammatory arthritis.

Schoettler N, Brahn E.

Curr Opin Investig Drugs. 2009 May;10(5):425-33. Review.

PMID:
19431075
14.

Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458.

Brahn E, Schoettler N, Lee S, Banquerigo ML.

J Pharmacol Exp Ther. 2009 May;329(2):615-24. doi: 10.1124/jpet.108.148478. Epub 2009 Feb 13.

15.
16.

Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of the literature.

Yao Q, Altman RD, Brahn E.

Semin Arthritis Rheum. 2009 Jun;38(6):458-66. doi: 10.1016/j.semarthrit.2008.07.001. Epub 2008 Aug 29. Review.

PMID:
18760449
17.

Inflammatory lipids as a target for therapy in the rheumatic diseases.

McMahon M, Brahn E.

Expert Opin Investig Drugs. 2008 Aug;17(8):1213-24. doi: 10.1517/13543784.17.8.1213 . Review.

PMID:
18616417
18.

Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis.

Charles-Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, Wagner AC, Fogelman AM, Brahn E.

Clin Immunol. 2008 May;127(2):234-44. doi: 10.1016/j.clim.2008.01.016. Epub 2008 Mar 12.

PMID:
18337176
19.

Vanadate, an inhibitor of stromelysin and collagenase expression, suppresses collagen induced arthritis.

Oliver SJ, Firestein GS, Arsenault L, Cruz TF, Cheng TP, Banquerigo ML, Boyle DL, Brahn E.

J Rheumatol. 2007 Sep;34(9):1802-9. Epub 2007 Aug 1.

PMID:
17696279
20.

Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis.

Lainer-Carr D, Brahn E.

Nat Clin Pract Rheumatol. 2007 Aug;3(8):434-42. Review.

PMID:
17664950
21.

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.

Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E.

Clin Immunol. 2007 Sep;124(3):244-57. Epub 2007 May 29.

PMID:
17537677
22.

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.

Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP.

Arthritis Rheum. 2006 Sep;54(9):2951-62.

23.

New antiangiogenic strategies for the treatment of proliferative synovitis.

Lainer DT, Brahn E.

Expert Opin Investig Drugs. 2005 Jan;14(1):1-17. Review.

PMID:
15709917
24.

Is erythrocyte sedimentation rate the preferable measure of the acute phase response in rheumatoid arthritis?

Paulus HE, Brahn E.

J Rheumatol. 2004 May;31(5):838-40. Review. No abstract available.

PMID:
15124238
25.

Angiocentric T cell lymphoma of the central nervous system in a patient with Sjögren's syndrome.

Khanna D, Vinters HV, Brahn E.

J Rheumatol. 2002 Jul;29(7):1548-50.

PMID:
12136918
26.

Environmental modulation of autoimmune arthritis involves the spontaneous microbial induction of T cell responses to regulatory determinants within heat shock protein 65.

Moudgil KD, Kim E, Yun OJ, Chi HH, Brahn E, Sercarz EE.

J Immunol. 2001 Mar 15;166(6):4237-43. Erratum in: J Immunol 2001 Jun 1;166(11):6992.

28.

Suppression of coronary vasculitis in a murine model of Kawasaki disease using an angiogenesis inhibitor.

Brahn E, Lehman TJ, Peacock DJ, Tang C, Banquerigo ML.

Clin Immunol. 1999 Jan;90(1):147-51.

PMID:
9884364
29.

Collagen induced arthritis: reversal by mercaptoethylguanidine, a novel antiinflammatory agent with a combined mechanism of action.

Brahn E, Banquerigo ML, Firestein GS, Boyle DL, Salzman AL, Szabó C.

J Rheumatol. 1998 Sep;25(9):1785-93.

PMID:
9733461
30.

The effect of thalidomide and 2 analogs on collagen induced arthritis.

Oliver SJ, Cheng TP, Banquerigo ML, Brahn E.

J Rheumatol. 1998 May;25(5):964-9.

PMID:
9598899
31.

Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis.

Crew MD, Effros RB, Walford RL, Zeller E, Cheroutre H, Brahn E.

J Interferon Cytokine Res. 1998 Apr;18(4):219-25.

PMID:
9568723
32.

Taxol involution of collagen-induced arthritis: ultrastructural correlation with the inhibition of synovitis and neovascularization.

Arsenault AL, Lhoták S, Hunter WL, Banquerigo ML, Brahn E.

Clin Immunol Immunopathol. 1998 Mar;86(3):280-9.

PMID:
9557161
33.
34.

Rheumatoid arthritis: current clinical and research directions.

Grossman JM, Brahn E.

J Womens Health. 1997 Dec;6(6):627-38. Review.

PMID:
9437637
36.
37.

Combination therapy in rheumatoid arthritis: the animal model perspective.

Oliver SJ, Brahn E.

J Rheumatol Suppl. 1996 Mar;44:56-60. Review.

PMID:
8833054
39.

A novel angiogenesis inhibitor suppresses rat adjuvant arthritis.

Peacock DJ, Banquerigo ML, Brahn E.

Cell Immunol. 1995 Feb;160(2):178-84.

PMID:
7536634
40.

Systemic lupus erythematosus: calciphylaxis induced cardiomyopathy.

MacLean C, Brahn E.

J Rheumatol. 1995 Jan;22(1):177-9.

PMID:
7699668
41.
42.

Regression of collagen-induced arthritis with taxol, a microtubule stabilizer.

Brahn E, Tang C, Banquerigo ML.

Arthritis Rheum. 1994 Jun;37(6):839-45.

PMID:
7911665
43.

Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen.

Ku G, Kronenberg M, Peacock DJ, Tempst P, Banquerigo ML, Braun BS, Reeve JR Jr, Brahn E.

Eur J Immunol. 1993 Mar;23(3):591-9.

PMID:
7680609
44.

Effects of tumor necrosis factor alpha (TNF-alpha) on collagen arthritis.

Brahn E, Peacock DJ, Banquerigo ML, Liu DY.

Lymphokine Cytokine Res. 1992 Oct;11(5):253-6.

PMID:
1467365
45.

Angiogenesis inhibition suppresses collagen arthritis.

Peacock DJ, Banquerigo ML, Brahn E.

J Exp Med. 1992 Apr 1;175(4):1135-8.

46.

Suppression of collagen arthritis with antibodies to an arthritogenic, oligoclonal T cell line.

Peacock DJ, Ku G, Banquerigo ML, Brahn E.

Cell Immunol. 1992 Apr;140(2):444-52.

PMID:
1347487
47.

Suppression of collagen-induced arthritis by combination cyclosporin A and methotrexate therapy.

Brahn E, Peacock DJ, Banquerigo ML.

Arthritis Rheum. 1991 Oct;34(10):1282-8.

PMID:
1930318
48.

Animal models of rheumatoid arthritis. Clues to etiology and treatment.

Brahn E.

Clin Orthop Relat Res. 1991 Apr;(265):42-53. Review.

PMID:
2009677
49.

Characterization of collagen-specific T cells derived from pathogenic and nonpathogenic rat T cell lines.

Ku G, Brahn E, Kronenberg M.

Cell Immunol. 1990 Oct 15;130(2):472-89.

PMID:
1698563
50.

Supplemental Content

Support Center